MeSH Browser

MeSH Heading: Abacavir
Tree Number(s): D02.455.426.392.368.533.001; D03.633.100.759.590.138.325.001; D13.570.230.229.001; D13.570.583.138.325.001
Unique ID: D000099227
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D000099227
Scope Note: A carbocyclic nucleoside reverse transcriptase inhibitor with potent and selective anti-HIV activity.
Entry Term(s): ((1R,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-cyclopent-2-enyl)methanol; ((1R,4S)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-enyl)methanol; (+)-Abacavir; (+)-Abacavir Sulfate; (+-)-Abacavir Sulfate; (-)-cis-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol; (1R,4R)-Abacavir; (1R,4S)-Abacavir Sulfate; (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol; (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol succinate (1:1) (salt); 1592U89; 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1R,4S)-, sulfate (2:1); 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)-, rel-, sulfate (2:1); 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, hydrochloride, hydrate (1:1:1), (1S,4R)-; Abacavir Hydrochloride Monohydrate; Abacavir Succinate; Abacavir Sulfate; Abacavir Sulfate Racemic; Abacavir Sulfate, (+)-; Abacavir Sulfate, (+-)-; Abacavir Sulfate, (1R,4S)-; Abacavir Sulphate; Abacavir enantiomer; Abacavir, (1R,4S)-; Abacavir, Trans-, (+-)-; Abacavir, trans-; Abamune; Avacavir; DRG 0257; DRG-0257; DRG0257; Ziagen; abacavir, (+)-; trans-Abacavir; trans-Abacavir R,R-
Pharm Action: Reverse Transcriptase Inhibitors
Anti-HIV Agents
Registry Numbers: WR2TIP26VS; 0; J220T4J9Q2; 40FH6D8CHK; GZP7A66C3C; PMA9EH08PM; 0903H757IU; 1PPL256S5A; X9A7099R51; 6BVN3YCO99
Related Numbers: 0903H757IU; 1PPL256S5A; 40FH6D8CHK; 6BVN3YCO99; GZP7A66C3C; J220T4J9Q2; PMA9EH08PM; X9A7099R51
Public MeSH Note: 2026; ABACAVIR was indexed under CYCLOPROPANES; DEOXYADENOSINES 1997-2025
History Note: 2026 (1997)
Date Introduced: 2026/01/01
Last Updated: 2026/01/01

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Organic Chemicals [D02]
- Hydrocarbons [D02.455]
  - Hydrocarbons, Cyclic [D02.455.426]
    - Hydrocarbons, Alicyclic [D02.455.426.392]
      - Cycloparaffins [D02.455.426.392.368]
        
        Cyclopropanes [D02.455.426.392.368.533]
        
        Abacavir [D02.455.426.392.368.533.001]
        
        Cilastatin [D02.455.426.392.368.533.200]
        
        Hypoglycins [D02.455.426.392.368.533.450]
        
        Milnacipran [D02.455.426.392.368.533.725]

Heterocyclic Compounds [D03]
- Heterocyclic Compounds, Fused-Ring [D03.633]
  - Heterocyclic Compounds, 2-Ring [D03.633.100]
    - Purines [D03.633.100.759]
      - Purine Nucleosides [D03.633.100.759.590]
        
        Adenosine [D03.633.100.759.590.138]
        
        Deoxyadenosines [D03.633.100.759.590.138.325]
        
        Abacavir [D03.633.100.759.590.138.325.001]
        
        Cladribine [D03.633.100.759.590.138.325.075]
        
        Dideoxyadenosine [D03.633.100.759.590.138.325.105]
        
        Puromycin Aminonucleoside [D03.633.100.759.590.138.325.800]

Nucleic Acids, Nucleotides, and Nucleosides [D13]
- Nucleosides [D13.570]
  - Deoxyribonucleosides [D13.570.230]
    - Deoxyadenosines [D13.570.230.229]

Nucleic Acids, Nucleotides, and Nucleosides [D13]
- Nucleosides [D13.570]
  - Purine Nucleosides [D13.570.583]
    - Adenosine [D13.570.583.138]
      - Deoxyadenosines [D13.570.583.138.325]
        
        Abacavir [D13.570.583.138.325.001]
        
        Cladribine [D13.570.583.138.325.075]
        
        Dideoxyadenosine [D13.570.583.138.325.105]
        
        Puromycin Aminonucleoside [D13.570.583.138.325.800]

Abacavir Preferred

Concept UI: M000768993
Registry Numbers: WR2TIP26VS
Related Numbers: 0903H757IU; 1PPL256S5A; 40FH6D8CHK; 6BVN3YCO99; GZP7A66C3C; J220T4J9Q2; PMA9EH08PM; X9A7099R51
Scope Note: A carbocyclic nucleoside reverse transcriptase inhibitor with potent and selective anti-HIV activity.
Terms: Abacavir Preferred Term
Term UI T001148308
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026); (-)-cis-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol
Term UI T001123225
Date08/10/2022
LexicalTag NON
ThesaurusID FDA SRS (2017); (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol
Term UI T307561
Date01/01/1955
LexicalTag NON
ThesaurusID NLM (1997); Avacavir
Term UI T001148309
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026)

Ziagen Narrower

Abacavir Sulfate Narrower

Abacavir Succinate Narrower

Abacavir Hydrochloride Monohydrate Narrower

Abacavir Sulfate, (+)- Narrower

1592U89 Narrower

Abamune Narrower

trans-Abacavir Narrower

(+-)-Abacavir Sulfate Narrower

(+)-Abacavir Narrower

Concept UI: M000758052
Registry Numbers: X9A7099R51
Terms: (+)-Abacavir Preferred Term
Term UI T001148310
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026); ((1R,4S)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-enyl)methanol
Term UI T001123280
Date08/10/2022
LexicalTag NON
ThesaurusID; Abacavir enantiomer
Term UI T001148311
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026); abacavir, (+)-
Term UI T001148330
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026); Abacavir, (1R,4S)-
Term UI T001148313
Date04/30/2025
LexicalTag NON
ThesaurusID NLM (2026)

(1R,4R)-Abacavir Narrower

DRG-0257 Narrower

Abacavir MeSH Descriptor Data 2026